Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SCN1A | P35498 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207398 | 0.93 | ALDH1A1 (0.68) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1911879 | 0.88 | NPC1 (0.69) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4233034 | 0.87 | NPC1 (0.67) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1605290 | 0.87 | NPC1 (0.67) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1643217 | 0.87 | NPC1 (0.71) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2946059 | 0.87 | NPC1 (0.71) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12311750 | 0.86 | NPC1 (0.70) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14035654 | 0.86 | NPC1 (0.70) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1911850 | 0.86 | NPC1 (0.66) | NPC1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13091445 | 0.86 | KDM4E (0.71) | NPC1MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | NPC1 1683/4885MEN1 3379/4885KMT2A 2165/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | NPC1 1963/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | NPC1 1963/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | NPC1 1963/4885MEN1 3330/4885KMT2A 1722/4885 |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | NPC1 3662/4885MEN1 4039/4885KMT2A 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.